Continuous subcutaneous insulin infusion (CSII) using an external insulin pump for the treatment of type 2 diabetes;Traitement du diabète de type 2 par perfusion sous-cutanée continue d'insuline par pompe externe.

Diabetes and Metabolism

Volumn 36, Issue 6, 2010, Pages 415-421

  Reznik, Y ^a  

^a CHU CÔTE DE NACRE   (France)

Author keywords

CSII; Diabetes; External insulin pump; HbA1c; Intensified insulin therapy; Review; Type 2 diabetes

Indexed keywords

HEMOGLOBIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN;

BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTINUOUS SUBCUTANEOUS INSULIN INFUSION; DIABETIC PATIENT; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN ALLERGY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PREGNANCY; QUALITY OF LIFE; REVIEW;

DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INFUSION PUMPS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 78649981228     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.08.002     Document Type: Review

References (36)

1. Gerich J. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998, 19:491-503.
2. Polonsky K.S., Given B.D., Hirsch L.J., Tillil H., Shapiro E.T., Beebe C., et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1998, 318:1231-1239.
3. Temple R.C., Carrington C.A., Luzio S.D., Owens D.R., Schneider A.E., Sobey W.J., et al. Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989, 1:293-295.
4. Group UKPD.S. Overview of 6 years' therapy of type II diabetes: a progressive disease (UKPDS 16). Diabetes 1995, 44:1249-1258.
5. Lassmann-Vague V., Clavel S., Guerci B., Hanaire H., Leroy R., Loeuille G.A., et al. Position Statement. When to treat a diabetic patient using an external insulin pump. Expert consensus. Société francophone du diabète (ex ALFEDIAM) 2009. Diabetes Metab 2010, 36:79-85.
6. Garvey W.T., Olefsky J.M., Griffin J., Hamman R.F., Kolterman O.G. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985, 34:222-234.
7. Gormley M.J., Hadden D.R., Woods R., Sheridan B., Andrews W.J. One month's insulin treatment of type II diabetes: the early and medium-term effects following insulin withdrawal. Metabolism 1986, 35:1029-1036.
8. Andrews W.J., Vasquez B., Nagulesparan M., Klimes I., Foley J., Unger R., et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 1984, 33:634-642.
9. Pouwels M.J., Tack C.J., Hermust A.R., Lutterman J.A. Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant type 2 diabetic patients. Diabet Med 2003, 20:76-79.
10. Wainstein J., Metzger M., Wexler I.D., Cohen J., Raz I. The use of continuous insulin delivery systems in severely insulin-resistant patients. Diabetes Care 2001, 24:1299.
11. Knee T.S., Seidensticker D.F., Walton J.L., Solbero L.M., Lasseter D.H. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract 2003, 9:181-186.
12. Lane W.S., Weinrib S.L., Rappaport J.M., Przestrzekski T. A prospective trial of U-500 insulin delivered by omnipod in patients in type 2 diabetes and severe insulin resistance. Endocr Pract 2010, 29:1-30.
13. Edelman S, Bode B, Bailey T, Kipnes M, Frias J. Continuous subcutaneous insulin infusion in patients with type 2 diabetes safely improved glycaemic control using a simple insulin design regimen. Diabetes ADA, 2009 [abstract 428P].
14. Kesavadev J., Balakrishnan S., Ahammed S., Jothydev S. Reduction of glycosylated haemoglobin following 6 months of continuous subcutaneous insulin infusion in an Indian population with type 2 diabetes. Diabetes Technol Ther 2009, 11:517-521.
15. Reznik Y, Morera J, Rod A, Coffin C, Rousseau E et Joubert M. Efficacy of Continuous Subcutaneous Insulin Infusion (CSII) in Type 2 Diabetes Mellitus: a Survey on a Cohort of 102 patients with prolonged follow-up. Diabetes Technol Therap [in press].
16. Raskin P., Bode B.W., Marks J.B., Hirsch I.B., Weinstein R.L., Mc Gill J.B., et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes. Diabetes Care 2003, 26:2598-2603.
17. Herman W.H., Ilag L.L., Johnson S.L., Martin C.L., Sinding J., Harthi A.A., et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005, 28:1568-1573.
18. Berthe E., Lireux B., Coffin C., Goulet-Salmon B., Houlbert D., Boutreux S., et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous insulin infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res 2007, 39:224-229.
19. Wainstein J., Metzger M., Boaz M., Minuchin O., Cohen Y., Yaffe A., et al. Insulin pump therapy vs multiple daily injections in obese type 2 diabetic patients. Diabet Med 2005, 22:1037-1046.
20. Jeitler K., Horvath K., Berghold A., Gratzer T.W., Neeser K., Pieber T.R., et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008, 51:941-951.
21. Fatourechi M.M., Kudva Y.C., Murad M.H., Elamin M.B., Tabini C.C., Montori V.M. Clinical review: Hypoglycaemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009, 94:729-740.
22. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992, 13:415-431.
23. Vuorinen-Markkola H., Koivisto V.A., Yki-Jarvinen H. Mechanism of hyperglycaemia-induced insulin resistance in whole body and skeletal muscle of type 1 diabetic patients. Diabetes 1992, 41:571-580.
24. Ilkova H., Glaser B., Tunckale A., Bagriacik N., Cerasi E. Induction of long-term glycaemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997, 20:1353-1356.
25. McFarlane S.I., Chaiken R.L., Hirsch S., Harrington P., Lebovitz H.E., Banerji M.A. Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 2001, 18:10-16.
26. Weng J., Li Y., Xu W., Shi L., Zhang Q., Zhu D., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicenter randomised parallel-group trial. Lancet 2008, 37:1753-1760.
27. Simmons D., Thompson C.F., Conroy C., Scott D.J. Use of insulin pumps in pregnancies complicated by type 2 diabetes and gestational diabetes in a multiethnic community. Diabetes Care 2001, 24:2078-2082.
28. Moyes V., Driver R., Croom A., Mirakian R., Chowdhury T.A. Insulin allergy in a patient with type 2 diabetes successfully treated with continuous subcutaneous insulin infusion. Diabet Med 2006, 23:204-206.
29. Radermecker R.P., Scheen A.J. Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues. Diabetes Metab Res Rev 2007, 23:348-355.
30. Wulffelé M.G., Kooy A., Lehert P., Bets D., Ogterop J.C., Borger van der Burg B., et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002, 12:2133-2140.
31. Labrousse-Lhermine F., Cazals L., Ruidavets J.B., the GEDEC Study Group, Hanaire H. Long-term treatment combining continuous subcutaneous insulin infusion with oral hypoglycaemic agents is effective in type 2 diabetes. Diabetes Metab 2007, 33:253-260.
32. Parkner T., Møller M.K., Chen J.W., Laursen T., Jørgensen C., Smedegaard J.S., et al. Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes. Diabetes Obes Metab 2008, 10:556-563.
33. Roze S., Valentine W.J., Zakrzewska K.E., Palmer A.J. Health economic comparison of continuous subcutaneaous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabet Med 2005, 22:1239-1245.
34. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007, 30:194-196.
35. Pickup J.C., Renard E. Long acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008, 31:S140-S145.
36. Saudek C.D., Duckworth W.C., Giobbie-Hurder A., Henderson W.G., Henry R.R., Kelley D.E., et al. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. JAMA 1996, 276:1322-1327.